Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latuda adjunctive to lithium or divalproex in bipolar I depression
NCT00868452Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Apr 2009
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of lurasidone in bipolar I disorder, sponsored by Sumitomo Pharma America. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 6 weeks. Started Apr 2009; status: completed.
02
Drugs
lurasidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00868452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00868452.